– USA, CA – ChromaCode, Inc., a company that combines data science and proprietary reagents to improve clinical molecular analysis, today announced the appointments of Pat Balthrop and Kevin O’Boyle to its Board of Directors.
“We are very fortunate to welcome Pat and Kevin to the board and look forward to benefiting from their vast experience in molecular diagnostics. Their expertise adds a wealth of industry know-how and will support execution of our long-term strategy.” said Executive Chairman and co-founder, Alex Dickinson.
“We are expanding the Board to include long-tenured leadership in our targeted markets,” said CEO and co-founder, Greg Gosch. “Pat’s and Kevin’s breadth of expertise will be invaluable as we expand our footprint in oncology, reproductive health, and infectious disease using our HDPCR™ technology.”
About Pat Balthrop
Mr. Balthrop is the former CEO and President of Luminex, a pioneer in multiplexed diagnostics platform development; chairman of the Board at Agendia, Inc, a molecular diagnostic company focused on oncology diagnostics for breast cancer; chairman of Discovery Life Sciences, a world leader in biospecimen and biomarker services; and a founding principal of Apalachee Ventures, LLC.
About Kevin O’Boyle
Mr. O’Boyle was most recently Chairman of the Board of Directors at GenMark Diagnostics, a leading provider of sample-to-answer molecular diagnostic solutions acquired by Roche in March 2021; and is currently a member of the Board of Directors at Nevro and Sientra.
About ChromaCode
ChromaCode is a diagnostic company providing proprietary reagents with scalable cloud analytics to dramatically improve clinical molecular analysis. The company’s unique core of data scientists and molecular biologists leverages patented mathematical methods and algorithms to extract new information from biochemistry reactions. This approach substantially increases the performance capabilities of today’s gold-standard molecular diagnostics instruments at a very low cost.
For more information: https://chromacode.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
